The drug from vaginal candidiasis (thrush) :: Consumers survey results of for 1 quarter of 2016

Consumers survey results of for 1 quarter of 2016 in category

Gynecology, urology, nephrology / The drug from vaginal candidiasis (thrush)

The annual ratings by results of Consumers survey calculated as average arithmetic mean rank, obtained in each of 4 quarters of year.

	I quarter (january—march)
	II quarter (april—june)
	III quarter (july—september)
	IV quarter (october—december)

1.	7	Кандібене (ratiopharm)	31.58%	5

1.		Флуконазол-Дарниця (Darnitsa)	31.58%	5

3.		Ливарол (Nizhpharm)	26.32%	4.17

3.	2	Пімафуцин (Delta Medical)	26.32%	4.17

5.		Дифлюкан (Pfizer Inc.)	21.05%	3.33

6.	7	Гінофорт (Gedeon Richter)	15.79%	2.50

6.	2	Дифлюзол (Arterium Corporation)	15.79%	2.50

6.		Мікогель-КМП (Arterium Corporation)	15.79%	2.50

6.	4	Флуомизин (Delta Medical)	15.79%	2.50

10.	6	Кандид (Glenmark Farmaceuticals Limited)	10.53%	1.67

10.	5	Кетодин (Сперко Україна)	10.53%	1.67

10.	1	Клотримазол (ORGANOSYN)	10.53%	1.67

10.	5	Мікомакс (Zentiva)	10.53%	1.67

–.	7	Мікогал (Teva)	0.00%	0

–.	5	Мікосист (Gedeon Richter)	0.00%	0

–.	7	Флунол (Нобель Ілач)	0.00%	0

Using this rating is only possible with obligatory link to the source.

This rating was built as a result of the study of social preferences in 2016, under the “Favorites of Success” Contest in Ukraine and it’s the free information. In case of full or partial republishing of the information drawn from this rating, it is obligatory to mention the name of the “Favorites of Success” Contest in printed publications, or put an active hyperlink to this page in the electronic media.

Advanced reporting booklet about the study, including demographics of the respondents, by regional breakdown, information roll-call of ad hoc judges etc, can also be obtained from managers of the contest.